FindMyRecallSubscribe
Class I: serious health riskTerminated

Pfizer 0.5% Bupivacaine Hydrochloride Injection Recall

0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dos…

PFIZER, INC · Lake Forest, IL

Risk level
Class I
Reported by FDA
Jun 9, 2021
Recall ID
D-0626-2021
Check your lot numberHow we source this data

Summary

Pfizer recalled 0.5% Bupivacaine Hydrochloride Injection starting May 3, 2021. The FDA classified it as Class I (serious health risk) and published enforcement report D-0626-2021 on Jun 9, 2021. Reason: Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP. Status: Terminated.

Why it was recalled

Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP

Product description

0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.

Lot numbers, UPCs & expiration codes

Lot EG6023, Exp. 07/01/2022

Where it was sold

Nationwide in the USA, Puerto Rico, and Guam

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0626-2021
Classification
Class I
Status
Terminated
Recall initiated
May 3, 2021
FDA report date
Jun 9, 2021
Quantity
163,957 vials
Recall type
Voluntary: Firm initiated
Recalling firm
PFIZER, INC

Original FDA data

Every field from FDA enforcement report D-0626-2021, exactly as published.

Show all FDA fields
City
Lake Forest
State
IL
Status
Terminated
Country
United States
Event ID
87837
Address
275 N Field Dr Bldg H3-3N
Code information
Lot EG6023, Exp. 07/01/2022
Postal code
60045-2579
Report date
Jun 9, 2021
Product type
Drugs
Recall number
D-0626-2021
Classification
Class I
Recalling firm
PFIZER, INC
Product quantity
163,957 vials
Termination date
Apr 4, 2023
Reason for recall
Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
Voluntary / mandated
Voluntary: Firm initiated
Product description
0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.
Distribution pattern
Nationwide in the USA, Puerto Rico, and Guam
Recall initiation date
May 3, 2021
Initial firm notification
Letter
Center classification date
Jun 10, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0626-2021, published Jun 9, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls